Apixaban NDC 0115-1722

NDC codes

FDA NDC Directory

Product NDC (as listed)0115-1722Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00115-1722Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0115-1722-01	00115172201	10 BLISTER PACK in 1 CARTON (0115-1722-01) / 10 TABLET, FILM COATED in 1 BLISTER PACK (0115-1722-15)Marketed from Aug 31, 2018
0115-1722-03	00115172203	1000 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0115-1722-03)Marketed from Aug 31, 2018
0115-1722-13	00115172213	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0115-1722-13)Marketed from Aug 31, 2018

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Apixaban
Generic name (nonproprietary): apixaban
Active ingredients: Apixaban — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Amneal Pharmaceuticals of New York LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209810
Marketing start: Aug 31, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Factor Xa Inhibitors (Mechanism)
Identifiers: Product ID 0115-1722_ac3db938-22a3-42a0-ac3a-8628d9e0a7cfSPL ID ac3db938-22a3-42a0-ac3a-8628d9e0a7cfSPL set ID 19a60552-374d-4b8b-a8ce-ceae252ea5baRxCUI 1364435, 1364445UNII 3Z9Y7UWC1JUPC 0301151721135, 0301151722132
Pharmacologic class: Factor Xa Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400115172201 followed by a unit qualifier and the quantity

Package 00115-1722-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 23, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

Apixaban tablets are a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209810

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209810
Product	Strength	Form · route	Labeler	Product NDC
Apixaban	Apixaban 2.5 mg/1	Tablet, Film coatedOral	Amneal Pharmaceuticals of New York LLC	0115-1721